Company profile: Aimmune Therapeutics
1.1 - Company Overview
Company description
- Provider of characterized oral desensitization immunotherapy for food allergies, including PALFORZIA to reduce the frequency and severity of reactions to accidental peanut exposure. Develops investigational therapies for food, gastrointestinal, and metabolic-related diseases, conducts human clinical trials to support marketing applications to regulatory authorities, and offers an expanded access policy compliant with FDA regulations.
Products and services
- PALFORZIA: A characterized oral immunotherapy product that desensitizes peanut-allergic patients, reducing frequency and severity of reactions—including anaphylaxis—following accidental exposure to peanuts
- Clinical Trials: Human, regulatory-facing studies conducted to demonstrate safety and efficacy of investigational products, generating evidence to support marketing applications submitted to regulatory authorities
- Pipeline Candidates: Investigational-stage therapies under development for food, gastrointestinal (GI), and metabolic-related diseases that aim to expand patient treatment options across these indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aimmune Therapeutics
Pheast
HQ: United States
Website
- Description: Provider of checkpoint therapies to harness the innate immune system, including PHST001, an anti-CD24 antibody that blocks a key macrophage ‘don’t eat me’ signal on cancer cells to induce an anti-cancer immune response, and a proprietary discovery platform that uncovers tumor-specific ‘don’t eat me’ signals to create novel macrophage-targeted immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheast company profile →
Memo Therapeutics
HQ: Switzerland
Website
- Description: Provider of antibody discovery and immune repertoire analysis, featuring the MemoMAB platform to create and bank recombinant copies of individual B cell/antibody repertoires for high-throughput functional screening to identify potent, ultra-rare antibodies. Offers human antibody repertoire libraries, discovery in humans and rabbits, and AntiBKV for BK virus in kidney transplant recipients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Memo Therapeutics company profile →
Baliopharm
HQ: Germany
Website
- Description: Provider of novel therapeutics developing monoclonal and bispecific antibodies for autoimmune diseases, chronic liver diseases such as NASH, B-cell malignancies, and cancer. Products include Atrosab and Atrosimab, TNF-R1 targeting antibodies for liver and immune-mediated inflammatory diseases, and Novotarg, a CD20/CD95-targeting bispecific for autoimmune diseases and B-cell malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baliopharm company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
Oncolytics Biotech
HQ: Canada
Website
- Description: Provider of oncolytic virus therapeutics for a broad range of cancers, developing Pelareorep, a nonpathogenic oncolytic virus that selectively replicates in cancer cells to generate immune responses, enhance oncology treatments, and extend patient survival.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncolytics Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aimmune Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aimmune Therapeutics
2.2 - Growth funds investing in similar companies to Aimmune Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aimmune Therapeutics
4.2 - Public trading comparable groups for Aimmune Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →